Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

In this phase 1/2 study, brentuximab vedotin (BV) and nivolumab (Nivo) administered in combination were evaluated as initial salvage therapy in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL). Patients received up to 4 cycles of combination treatment, with BV administered...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Herrera, Alex F., Moskowitz, Alison J., Bartlett, Nancy L., Vose, Julie M., Ramchandren, Radhakrishnan, Feldman, Tatyana A., LaCasce, Ann S., Ansell, Stephen M., Moskowitz, Craig H., Fenton, Keenan, Ogden, Carol Anne, Taft, David, Zhang, Qu, Kato, Kazunobu, Campbell, Mary, Advani, Ranjana H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2018
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5855021/
https://ncbi.nlm.nih.gov/pubmed/29229594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-10-811224
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi